BIAL launches KYNMOBI® in Germany
The first sublingual therapy for the on-demand treatment of OFF episodes in Parkinson’s disease
BIAL appoints Pierluigi Antonelli as Non-Executive Board Member
BIAL appoints Pierluigi Antonelli as Non-Executive Board Member
BIAL celebrates its centenary in 2024
BIAL celebrates its centenary in 2024. Initiatives planned throughout the year will establish relationships with employees, partners and the community.
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
BIAL to discuss scientific advances in Epilepsy
BIAL to discuss scientific advances in Epilepsy
BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156
BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson’s Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene.
BIAL Appoints Melanie Lee As Non-Executive Board Member
BIAL Appoints Melanie Lee As Non-Executive Board Member
BIAL appoints Max Bricchi as Chief Commercial Officer
BIAL has announced the appointment of Max Bricchi as Chief Commercial Officer (CCO) and Executive Board member.
Scientist.com Announces Launch of Research Marketplace for BIAL
PScientist.com Announces Launch of Research Marketplace for BIAL BIAL partners with Scientist.com to improve and digitize internal R&D
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.